Special Use-results Survery of Rituxan Intravenous Injection - Relapse Prevention of Neuromyelitis Optica Spectrum Disorder (including Neuromyelitis Optica)
Not Applicable
Recruiting
- Conditions
- neuromyelitis optica spectrum disorder (including neuromyelitis optica)
- Registration Number
- JPRN-jRCT2031220487
- Lead Sponsor
- Ando Takashi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Patients who have received Rituxan intravenous injection for relapse prevention of neuromyelitis optica spectrum disorder (including neuromyelitis optica)
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of adverse drug reactions and severe adverse events (including grade 3/4 laboratory abnormalities)
- Secondary Outcome Measures
Name Time Method